2023-12-21
|
R-HSA-9856649
|
Transcriptional and post-translational regulation of MITF-M expression and activity
|
BibTex
|
2023-12-21
|
R-HSA-9856651
|
MITF-M-dependent gene expression
|
BibTex
|
2023-12-21
|
R-HSA-9854907
|
Regulation of MITF-M dependent genes involved in metabolism
|
BibTex
|
2023-12-21
|
R-HSA-9854909
|
Regulation of MITF-M dependent genes involved in invasion
|
BibTex
|
2023-12-21
|
R-HSA-9857377
|
Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy
|
BibTex
|
2023-10-14
|
R-HSA-9842663
|
Signaling by LTK
|
BibTex
|
2023-10-14
|
R-HSA-9842640
|
Signaling by LTK in cancer
|
BibTex
|
2023-10-14
|
R-HSA-9851151
|
MDK and PTN in ALK signaling
|
BibTex
|
2023-01-26
|
R-HSA-9730414
|
MITF-M-regulated melanocyte development
|
BibTex
|
2023-01-26
|
R-HSA-9824585
|
Regulation of MITF-M-dependent genes involved in pigmentation
|
BibTex
|
2023-01-26
|
R-HSA-9825892
|
Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
|
BibTex
|
2023-01-26
|
R-HSA-9825895
|
Regulation of MITF-M-dependent genes involved in DNA damage repair and senescence
|
BibTex
|
2023-01-26
|
R-HSA-9824594
|
Regulation of MITF-M-dependent genes involved in apoptosis
|
BibTex
|
2021-10-08
|
R-HSA-9755511
|
KEAP1-NFE2L2 pathway
|
BibTex
|
2021-10-08
|
R-HSA-9759194
|
Nuclear events mediated by NFE2L2
|
BibTex
|
2021-10-08
|
R-HSA-9762114
|
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
|
BibTex
|
2021-03-30
|
R-HSA-9725370
|
Signaling by ALK fusions and activated point mutants
|
BibTex
|
2021-03-30
|
R-HSA-9725371
|
Nuclear events stimulated by ALK signaling in cancer
|
BibTex
|
2021-03-30
|
R-HSA-9701898
|
STAT3 nuclear events downstream of ALK signaling
|
BibTex
|
2021-03-22
|
R-HSA-9700206
|
Signaling by ALK in cancer
|
BibTex
|
2021-03-22
|
R-HSA-9700649
|
Drug resistance of ALK mutants
|
BibTex
|
2021-03-22
|
R-HSA-9717323
|
ceritinib-resistant ALK mutants
|
BibTex
|
2021-03-22
|
R-HSA-9717326
|
crizotinib-resistant ALK mutants
|
BibTex
|
2021-03-22
|
R-HSA-9717329
|
lorlatinib-resistant ALK mutants
|
BibTex
|
2021-03-22
|
R-HSA-9717264
|
ASP-3026-resistant ALK mutants
|
BibTex
|
2021-03-22
|
R-HSA-9717319
|
brigatinib-resistant ALK mutants
|
BibTex
|
2021-03-22
|
R-HSA-9717301
|
NVP-TAE684-resistant ALK mutants
|
BibTex
|
2021-03-22
|
R-HSA-9717316
|
alectinib-resistant ALK mutants
|
BibTex
|
2021-03-22
|
R-HSA-9700645
|
ALK mutants bind TKIs
|
BibTex
|
2021-02-17
|
R-HSA-9716542
|
Signaling by Rho GTPases, Miro GTPases and RHOBTB3
|
BibTex
|
2020-11-06
|
R-HSA-9682385
|
FLT3 signaling in disease
|
BibTex
|
2020-11-06
|
R-HSA-9702506
|
Drug resistance of FLT3 mutants
|
BibTex
|
2020-11-06
|
R-HSA-9702569
|
KW2449-resistant FLT3 mutants
|
BibTex
|
2020-11-06
|
R-HSA-9702600
|
midostaurin-resistant FLT3 mutants
|
BibTex
|
2020-11-06
|
R-HSA-9702632
|
sunitinib-resistant FLT3 mutants
|
BibTex
|
2020-11-06
|
R-HSA-9702605
|
pexidartinib-resistant FLT3 mutants
|
BibTex
|
2020-11-06
|
R-HSA-9702636
|
tandutinib-resistant FLT3 mutants
|
BibTex
|
2020-11-06
|
R-HSA-9703009
|
tamatinib-resistant FLT3 mutants
|
BibTex
|
2020-11-06
|
R-HSA-9702624
|
sorafenib-resistant FLT3 mutants
|
BibTex
|
2020-11-06
|
R-HSA-9702596
|
lestaurtinib-resistant FLT3 mutants
|
BibTex
|
2020-11-06
|
R-HSA-9702590
|
gilteritinib-resistant FLT3 mutants
|
BibTex
|
2020-11-06
|
R-HSA-9702620
|
quizartinib-resistant FLT3 mutants
|
BibTex
|
2020-11-06
|
R-HSA-9702577
|
semaxanib-resistant FLT3 mutants
|
BibTex
|
2020-11-06
|
R-HSA-9702998
|
linifanib-resistant FLT3 mutants
|
BibTex
|
2020-11-06
|
R-HSA-9702614
|
ponatinib-resistant FLT3 mutants
|
BibTex
|
2020-11-06
|
R-HSA-9702581
|
crenolanib-resistant FLT3 mutants
|
BibTex
|
2020-11-06
|
R-HSA-9703465
|
Signaling by FLT3 fusion proteins
|
BibTex
|
2020-11-06
|
R-HSA-9706377
|
FLT3 signaling by CBL mutants
|
BibTex
|
2020-11-06
|
R-HSA-9702509
|
FLT3 mutants bind TKIs
|
BibTex
|
2020-11-06
|
R-HSA-9703648
|
Signaling by FLT3 ITD and TKD mutants
|
BibTex
|
2020-11-06
|
R-HSA-9706369
|
Negative regulation of FLT3
|
BibTex
|
2020-11-06
|
R-HSA-9706374
|
FLT3 signaling through SRC family kinases
|
BibTex
|
2020-11-06
|
R-HSA-9702518
|
STAT5 activation downstream of FLT3 ITD mutants
|
BibTex
|
2020-07-30
|
R-HSA-9694516
|
SARS-CoV-2 Infection
|
BibTex
|
2020-07-30
|
R-HSA-9694322
|
Virion Assembly and Release
|
BibTex
|
2020-07-14
|
R-HSA-9012999
|
RHO GTPase cycle
|
BibTex
|
2020-07-14
|
R-HSA-9013148
|
CDC42 GTPase cycle
|
BibTex
|
2020-07-14
|
R-HSA-9013404
|
RAC2 GTPase cycle
|
BibTex
|
2020-07-14
|
R-HSA-9013149
|
RAC1 GTPase cycle
|
BibTex
|
2020-07-14
|
R-HSA-9013423
|
RAC3 GTPase cycle
|
BibTex
|
2020-04-22
|
R-HSA-9679509
|
Virion Assembly and Release
|
BibTex
|
2020-04-01
|
R-HSA-9669938
|
Signaling by KIT in disease
|
BibTex
|
2020-04-01
|
R-HSA-9669933
|
Signaling by kinase domain mutants of KIT
|
BibTex
|
2020-04-01
|
R-HSA-9669935
|
Signaling by juxtamembrane domain KIT mutants
|
BibTex
|
2020-04-01
|
R-HSA-9670439
|
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
|
BibTex
|
2020-04-01
|
R-HSA-9669937
|
Drug resistance of KIT mutants
|
BibTex
|
2020-04-01
|
R-HSA-9669917
|
Imatinib-resistant KIT mutants
|
BibTex
|
2020-04-01
|
R-HSA-9669934
|
Sunitinib-resistant KIT mutants
|
BibTex
|
2020-04-01
|
R-HSA-9669929
|
Regorafenib-resistant KIT mutants
|
BibTex
|
2020-04-01
|
R-HSA-9669914
|
Dasatinib-resistant KIT mutants
|
BibTex
|
2020-04-01
|
R-HSA-9669924
|
Masitinib-resistant KIT mutants
|
BibTex
|
2020-04-01
|
R-HSA-9669926
|
Nilotinib-resistant KIT mutants
|
BibTex
|
2020-04-01
|
R-HSA-9669936
|
Sorafenib-resistant KIT mutants
|
BibTex
|
2020-04-01
|
R-HSA-9669921
|
KIT mutants bind TKIs
|
BibTex
|
2020-03-24
|
R-HSA-9680187
|
Signaling by extracellular domain mutants of KIT
|
BibTex
|
2020-02-25
|
R-HSA-9671555
|
Signaling by PDGFR in disease
|
BibTex
|
2020-02-25
|
R-HSA-9674428
|
PDGFR mutants bind TKIs
|
BibTex
|
2020-02-25
|
R-HSA-9674415
|
Drug resistance of PDGFR mutants
|
BibTex
|
2020-02-25
|
R-HSA-9674396
|
Imatinib-resistant PDGFR mutants
|
BibTex
|
2020-02-25
|
R-HSA-9674404
|
Sorafenib-resistant PDGFR mutants
|
BibTex
|
2020-02-25
|
R-HSA-9674401
|
Sunitinib-resistant PDGFR mutants
|
BibTex
|
2020-02-25
|
R-HSA-9674403
|
Regorafenib-resistant PDGFR mutants
|
BibTex
|
2020-02-25
|
R-HSA-9673767
|
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
|
BibTex
|
2020-02-25
|
R-HSA-9673766
|
Signaling by cytosolic PDGFRA and PDGFRB fusion proteins
|
BibTex
|
2020-02-25
|
R-HSA-9673770
|
Signaling by PDGFRA extracellular domain mutants
|
BibTex
|
2020-02-25
|
R-HSA-9673768
|
Signaling by membrane-tethered fusions of PDGFRA or PDGFRB
|
BibTex
|
2020-01-31
|
R-HSA-9675108
|
Nervous system development
|
BibTex
|
2019-10-25
|
R-HSA-9648002
|
RAS processing
|
BibTex
|
2019-10-25
|
R-HSA-9656223
|
Signaling by RAF1 mutants
|
BibTex
|
2019-10-25
|
R-HSA-9652817
|
Signaling by MAPK mutants
|
BibTex
|
2019-10-25
|
R-HSA-9652169
|
Signaling by MAP2K mutants
|
BibTex
|
2019-10-25
|
R-HSA-9726840
|
SHOC2 M1731 mutant abolishes MRAS complex function
|
BibTex
|
2019-10-25
|
R-HSA-9726842
|
Gain-of-function MRAS complexes activate RAF signaling
|
BibTex
|
2019-10-25
|
R-HSA-9660537
|
Signaling by MRAS-complex mutants
|
BibTex
|
2019-08-16
|
R-HSA-9031628
|
NGF-stimulated transcription
|
BibTex
|
2019-08-16
|
R-HSA-9619665
|
EGR2 and SOX10-mediated initiation of Schwann cell myelination
|
BibTex
|
2018-12-15
|
R-HSA-9634635
|
Estrogen-stimulated signaling through PRKCZ
|
BibTex
|
2018-12-15
|
R-HSA-9634638
|
Estrogen-dependent nuclear events downstream of ESR-membrane signaling
|
BibTex
|
2018-12-15
|
R-HSA-9634597
|
GPER1 signaling
|
BibTex
|
2017-09-29
|
R-HSA-8939211
|
ESR-mediated signaling
|
BibTex
|
2017-09-29
|
R-HSA-9018519
|
Estrogen-dependent gene expression
|
BibTex
|
2017-09-29
|
R-HSA-9009391
|
Extra-nuclear estrogen signaling
|
BibTex
|
2017-05-24
|
R-HSA-9006934
|
Signaling by Receptor Tyrosine Kinases
|
BibTex
|
2017-05-24
|
R-HSA-9006931
|
Signaling by Nuclear Receptors
|
BibTex
|
2017-05-24
|
R-HSA-9006936
|
Signaling by TGFB family members
|
BibTex
|
2017-05-24
|
R-HSA-9006927
|
Signaling by Non-Receptor Tyrosine Kinases
|
BibTex
|
2017-05-24
|
R-HSA-9006925
|
Intracellular signaling by second messengers
|
BibTex
|
2017-05-19
|
R-HSA-9006821
|
Alternative Lengthening of Telomeres (ALT)
|
BibTex
|
2017-02-07
|
R-HSA-8951664
|
Neddylation
|
BibTex
|
2016-06-29
|
R-HSA-8876198
|
RAB GEFs exchange GTP for GDP on RABs
|
BibTex
|
2016-06-29
|
R-HSA-9007101
|
Rab regulation of trafficking
|
BibTex
|
2016-06-03
|
R-HSA-8873719
|
RAB geranylgeranylation
|
BibTex
|
2016-05-11
|
R-HSA-8856828
|
Clathrin-mediated endocytosis
|
BibTex
|
2016-05-11
|
R-HSA-8856825
|
Cargo recognition for clathrin-mediated endocytosis
|
BibTex
|
2016-01-09
|
R-HSA-8853333
|
Signaling by FGFR2 fusions
|
BibTex
|
2016-01-09
|
R-HSA-8853334
|
Signaling by FGFR3 fusions in cancer
|
BibTex
|
2016-01-09
|
R-HSA-8853336
|
Signaling by plasma membrane FGFR1 fusions
|
BibTex
|
2016-01-09
|
R-HSA-8851708
|
Signaling by FGFR2 IIIa TM
|
BibTex
|
2016-01-06
|
R-HSA-8856688
|
Golgi-to-ER retrograde transport
|
BibTex
|
2015-11-09
|
R-HSA-6811442
|
Intra-Golgi and retrograde Golgi-to-ER traffic
|
BibTex
|
2015-11-09
|
R-HSA-6811438
|
Intra-Golgi traffic
|
BibTex
|
2015-11-09
|
R-HSA-6811434
|
COPI-dependent Golgi-to-ER retrograde traffic
|
BibTex
|
2015-11-09
|
R-HSA-6811436
|
COPI-independent Golgi-to-ER retrograde traffic
|
BibTex
|
2015-11-09
|
R-HSA-6811440
|
Retrograde transport at the Trans-Golgi-Network
|
BibTex
|
2015-10-07
|
R-HSA-6803529
|
FGFR2 alternative splicing
|
BibTex
|
2015-09-01
|
R-HSA-6807878
|
COPI-mediated anterograde transport
|
BibTex
|
2015-08-10
|
R-HSA-6802952
|
Signaling by BRAF and RAF1 fusions
|
BibTex
|
2015-08-10
|
R-HSA-6802953
|
RAS signaling downstream of NF1 loss-of-function variants
|
BibTex
|
2015-08-10
|
R-HSA-6802955
|
Paradoxical activation of RAF signaling by kinase inactive BRAF
|
BibTex
|
2015-08-10
|
R-HSA-6802946
|
Signaling by moderate kinase activity BRAF mutants
|
BibTex
|
2015-08-10
|
R-HSA-6802948
|
Signaling by high-kinase activity BRAF mutants
|
BibTex
|
2015-05-18
|
R-HSA-6802957
|
Oncogenic MAPK signaling
|
BibTex
|
2015-05-18
|
R-HSA-6802949
|
Signaling by RAS mutants
|
BibTex
|
2015-05-18
|
R-HSA-9649948
|
Signaling downstream of RAS mutants
|
BibTex
|
2015-05-18
|
R-HSA-9649913
|
RAS GTPase cycle mutants
|
BibTex
|
2015-05-18
|
R-HSA-9753512
|
Signaling by RAS GTPase mutants
|
BibTex
|
2015-04-17
|
R-HSA-5694530
|
Cargo concentration in the ER
|
BibTex
|
2015-03-30
|
R-HSA-5687128
|
MAPK6/MAPK4 signaling
|
BibTex
|
2015-03-11
|
R-HSA-5684996
|
MAPK1/MAPK3 signaling
|
BibTex
|
2015-03-10
|
R-HSA-5683057
|
MAPK family signaling cascades
|
BibTex
|
2015-02-12
|
R-HSA-5673001
|
RAF/MAP kinase cascade
|
BibTex
|
2015-02-12
|
R-HSA-5675221
|
Negative regulation of MAPK pathway
|
BibTex
|
2015-02-12
|
R-HSA-5673000
|
RAF activation
|
BibTex
|
2015-02-12
|
R-HSA-5674499
|
Negative feedback regulation of MAPK pathway
|
BibTex
|
2015-02-10
|
R-HSA-5674135
|
MAP2K and MAPK activation
|
BibTex
|
2014-12-18
|
R-HSA-5658442
|
Regulation of RAS by GAPs
|
BibTex
|
2014-12-12
|
R-HSA-5658623
|
FGFRL1 modulation of FGFR1 signaling
|
BibTex
|
2014-11-20
|
R-HSA-5655291
|
Signaling by FGFR4 in disease
|
BibTex
|
2014-11-20
|
R-HSA-5655302
|
Signaling by FGFR1 in disease
|
BibTex
|
2014-11-20
|
R-HSA-5655332
|
Signaling by FGFR3 in disease
|
BibTex
|
2014-11-20
|
R-HSA-5655253
|
Signaling by FGFR2 in disease
|
BibTex
|
2014-10-31
|
R-HSA-5635851
|
GLI proteins bind promoters of Hh responsive genes to promote transcription
|
BibTex
|
2014-10-30
|
R-HSA-5635838
|
Activation of SMO
|
BibTex
|
2014-10-20
|
R-HSA-5632681
|
Ligand-receptor interactions
|
BibTex
|
2014-09-19
|
R-HSA-5624958
|
ARL13B-mediated ciliary trafficking of INPP5E
|
BibTex
|
2014-09-15
|
R-HSA-5624138
|
Trafficking of myristoylated proteins to the cilium
|
BibTex
|
2014-08-28
|
R-HSA-5620912
|
Anchoring of the basal body to the plasma membrane
|
BibTex
|
2014-08-22
|
R-HSA-5620920
|
Cargo trafficking to the periciliary membrane
|
BibTex
|
2014-08-22
|
R-HSA-5620922
|
BBSome-mediated cargo-targeting to cilium
|
BibTex
|
2014-08-22
|
R-HSA-5620916
|
VxPx cargo-targeting to cilium
|
BibTex
|
2014-08-22
|
R-HSA-5620924
|
Intraflagellar transport
|
BibTex
|
2014-08-07
|
R-HSA-5617833
|
Cilium Assembly
|
BibTex
|
2014-08-07
|
R-HSA-5632684
|
Hedgehog 'on' state
|
BibTex
|
2014-05-22
|
R-HSA-5545619
|
XAV939 stabilizes AXIN
|
BibTex
|
2014-05-13
|
R-HSA-5658034
|
HHAT G278V doesn't palmitoylate Hh-Np
|
BibTex
|
2014-05-07
|
R-HSA-5610787
|
Hedgehog 'off' state
|
BibTex
|
2014-05-07
|
R-HSA-5610785
|
GLI3 is processed to GLI3R by the proteasome
|
BibTex
|
2014-05-07
|
R-HSA-5610783
|
Degradation of GLI2 by the proteasome
|
BibTex
|
2014-05-07
|
R-HSA-5610780
|
Degradation of GLI1 by the proteasome
|
BibTex
|
2014-04-30
|
R-HSA-5387390
|
Hh mutants abrogate ligand secretion
|
BibTex
|
2014-04-16
|
R-HSA-5362768
|
Hh mutants are degraded by ERAD
|
BibTex
|
2014-04-16
|
R-HSA-5362798
|
Release of Hh-Np from the secreting cell
|
BibTex
|
2014-04-03
|
R-HSA-5358749
|
CTNNB1 S37 mutants aren't phosphorylated
|
BibTex
|
2014-04-03
|
R-HSA-5339700
|
Signaling by TCF7L2 mutants
|
BibTex
|
2014-04-02
|
R-HSA-5358751
|
CTNNB1 S45 mutants aren't phosphorylated
|
BibTex
|
2014-04-02
|
R-HSA-5358747
|
CTNNB1 S33 mutants aren't phosphorylated
|
BibTex
|
2014-04-02
|
R-HSA-5358752
|
CTNNB1 T41 mutants aren't phosphorylated
|
BibTex
|
2014-03-24
|
R-HSA-5358351
|
Signaling by Hedgehog
|
BibTex
|
2014-03-24
|
R-HSA-5358346
|
Hedgehog ligand biogenesis
|
BibTex
|
2014-03-11
|
R-HSA-5340588
|
Signaling by RNF43 mutants
|
BibTex
|
2014-03-11
|
R-HSA-5340573
|
LGK974 inhibits PORCN
|
BibTex
|
2014-02-22
|
R-HSA-5339716
|
Signaling by GSK3beta mutants
|
BibTex
|
2014-02-22
|
R-HSA-5339717
|
Signaling by LRP5 mutants
|
BibTex
|
2014-01-23
|
R-HSA-5467345
|
Deletions in the AXIN1 gene destabilize the destruction complex
|
BibTex
|
2014-01-23
|
R-HSA-5467343
|
Deletions in the AMER1 gene destabilize the destruction complex
|
BibTex
|
2014-01-17
|
R-HSA-5467337
|
APC truncation mutants have impaired AXIN binding
|
BibTex
|
2014-01-17
|
R-HSA-5467333
|
APC truncation mutants are not K63 polyubiquitinated
|
BibTex
|
2013-11-01
|
R-HSA-4839735
|
Signaling by AXIN mutants
|
BibTex
|
2013-11-01
|
R-HSA-4839748
|
Signaling by AMER1 mutants
|
BibTex
|
2013-11-01
|
R-HSA-4839744
|
Signaling by APC mutants
|
BibTex
|
2013-11-01
|
R-HSA-5467340
|
AXIN missense mutants destabilize the destruction complex
|
BibTex
|
2013-11-01
|
R-HSA-4839743
|
Signaling by CTNNB1 phospho-site mutants
|
BibTex
|
2013-10-30
|
R-HSA-5467348
|
Truncations of AMER1 destabilize the destruction complex
|
BibTex
|
2013-10-07
|
R-HSA-4791275
|
Signaling by WNT in cancer
|
BibTex
|
2013-09-23
|
R-HSA-4641265
|
Repression of WNT target genes
|
BibTex
|
2013-09-23
|
R-HSA-4641263
|
Regulation of FZD by ubiquitination
|
BibTex
|
2013-09-19
|
R-HSA-4608870
|
Asymmetric localization of PCP proteins
|
BibTex
|
2013-08-24
|
R-HSA-201681
|
TCF dependent signaling in response to WNT
|
BibTex
|
2013-08-24
|
R-HSA-201688
|
WNT mediated activation of DVL
|
BibTex
|
2013-08-24
|
R-HSA-201722
|
Formation of the beta-catenin:TCF transactivating complex
|
BibTex
|
2013-08-24
|
R-HSA-4411364
|
Binding of TCF/LEF:CTNNB1 to target gene promoters
|
BibTex
|
2013-08-08
|
R-HSA-4086398
|
Ca2+ pathway
|
BibTex
|
2013-08-08
|
R-HSA-4086400
|
PCP/CE pathway
|
BibTex
|
2013-07-10
|
R-HSA-3858494
|
Beta-catenin independent WNT signaling
|
BibTex
|
2013-06-25
|
R-HSA-4641257
|
Degradation of AXIN
|
BibTex
|
2013-06-25
|
R-HSA-4641258
|
Degradation of DVL
|
BibTex
|
2013-06-25
|
R-HSA-4641262
|
Disassembly of the destruction complex and recruitment of AXIN to the membrane
|
BibTex
|
2013-05-30
|
R-HSA-3772470
|
Negative regulation of TCF-dependent signaling by WNT ligand antagonists
|
BibTex
|
2013-05-30
|
R-HSA-3769402
|
Deactivation of the beta-catenin transactivating complex
|
BibTex
|
2013-04-06
|
R-HSA-3238698
|
WNT ligand biogenesis and trafficking
|
BibTex
|
2012-02-10
|
R-HSA-1226099
|
Signaling by FGFR in disease
|
BibTex
|
2012-02-10
|
R-HSA-1839128
|
FGFR4 mutant receptor activation
|
BibTex
|
2012-02-10
|
R-HSA-1839126
|
FGFR2 mutant receptor activation
|
BibTex
|
2012-02-10
|
R-HSA-2023837
|
Signaling by FGFR2 amplification mutants
|
BibTex
|
2012-02-10
|
R-HSA-2033519
|
Activated point mutants of FGFR2
|
BibTex
|
2012-02-10
|
R-HSA-2033514
|
FGFR3 mutant receptor activation
|
BibTex
|
2012-02-10
|
R-HSA-1839130
|
Signaling by activated point mutants of FGFR3
|
BibTex
|
2012-02-10
|
R-HSA-1839117
|
Signaling by cytosolic FGFR1 fusion mutants
|
BibTex
|
2012-02-10
|
R-HSA-1839120
|
Signaling by FGFR1 amplification mutants
|
BibTex
|
2012-02-10
|
R-HSA-1839122
|
Signaling by activated point mutants of FGFR1
|
BibTex
|
2012-02-10
|
R-HSA-1839124
|
FGFR1 mutant receptor activation
|
BibTex
|
2012-02-10
|
R-HSA-2033515
|
t(4;14) translocations of FGFR3
|
BibTex
|
2011-08-15
|
R-HSA-1307965
|
betaKlotho-mediated ligand binding
|
BibTex
|
2011-08-15
|
R-HSA-5654733
|
Negative regulation of FGFR4 signaling
|
BibTex
|
2011-08-15
|
R-HSA-5654727
|
Negative regulation of FGFR2 signaling
|
BibTex
|
2011-08-15
|
R-HSA-5654726
|
Negative regulation of FGFR1 signaling
|
BibTex
|
2011-08-15
|
R-HSA-5654732
|
Negative regulation of FGFR3 signaling
|
BibTex
|
2011-08-15
|
R-HSA-1295596
|
Spry regulation of FGF signaling
|
BibTex
|
2005-05-06
|
R-HSA-162582
|
Signal Transduction
|
BibTex
|